GeoVax Advocates for Enhanced Pandemic Preparedness Amid Global Health Threats

GeoVax Labs, Inc., a clinical-stage biotechnology company, has issued a pressing call for the United States to bolster its pandemic preparedness and biodefense strategies. Highlighting the global spread of Mpox, the emergence of immune-evasive COVID-19 variants, and the reliance on foreign vaccine supplies, GeoVax underscores the urgency for domestic solutions to safeguard public health.

The company's vaccine platform features two key candidates: GEO-MVA for Mpox and smallpox, and GEO-CM04S1, a next-generation COVID-19 vaccine aimed at providing robust protection for immunocompromised individuals. These innovations are backed by Phase 2 clinical data and support from regulatory bodies, positioning GeoVax as a leader in the fight against infectious diseases.

Current health threats, including the spread of Clade I Mpox strains and the dominance of the NB.1.8.1 COVID-19 variant, highlight the vulnerabilities in the global health infrastructure. The Strategic National Stockpile's dependence on a single foreign supplier for Mpox vaccines exacerbates these challenges, prompting calls for a diversified and resilient supply chain.

Bipartisan support in Congress and initiatives by the Administration for Strategic Preparedness and Response (ASPR) reflect a growing consensus on the need for U.S.-based manufacturing and procurement of pandemic countermeasures. GeoVax aligns with these priorities, advocating for swift government action to enhance the nation's biodefense capabilities.

The global community's commitment to pandemic preparedness, as evidenced by the WHO Pandemic Agreement, underscores the importance of proactive measures. GeoVax's call to action emphasizes the need for investment in domestic vaccine production and stockpile diversification to mitigate the impact of future health crises.

For more information on GeoVax's initiatives and clinical trials, visit https://www.geovax.com.